206 related articles for article (PubMed ID: 36905762)
1. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
3. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
Hu B; Hu J
Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
5. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.
Busonero C; Leone S; Klemm C; Acconcia F
Mol Cell Endocrinol; 2018 Jan; 460():229-237. PubMed ID: 28760601
[TBL] [Abstract][Full Text] [Related]
6. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
7. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
8. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
10. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
[TBL] [Abstract][Full Text] [Related]
14. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
Thaler S; Schmidt M; Schad A; Sleeman JP
Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
[TBL] [Abstract][Full Text] [Related]
15. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.
Ko YM; Wu TY; Wu YC; Chang FR; Guh JY; Chuang LY
J Ethnopharmacol; 2011 Oct; 137(3):1283-90. PubMed ID: 21840388
[TBL] [Abstract][Full Text] [Related]
16. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
[TBL] [Abstract][Full Text] [Related]
17. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
Lin X; Xiang H; Luo G
Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
19. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]